3 November 1999 in JNCI: Journal of the National Cancer Institute
BACKGROUND: Fenretinide, a vitamin A analogue, has been shown to inhibit breast carcinogenesis in preclinical studies. We determined the efficacy of fenretinide in preventing a second breast malignancy in women with breast cancer. METHODS: We randomly assigned 2972 women, aged 30-70 years, with surgically removed stage I breast cancer or ductal carcinoma in situ to receive for 5 years either fenretinide orally (200 mg/day) or no treatment. The primary end point was the incidence of contralateral breast cancer or ipsilateral breast cancer 7 years after randomization. Other end points considered post hoc were the same outcomes stratified by menopausal status, incidence of distant metastases, overall mortality, and tumors in other organs. The hazards of breast cancer occurrence were determined by Cox proportional hazards regression analysis. Statistical tests were two-sided. RESULTS: At a median observation time of 97 months, there were no statistically significant differences in the occurrence of contralateral breast cancer (P = .642) or ipsilateral breast cancer (P = .177) between the two arms. However, an interaction was detected between fenretinide treatment and menopausal status in both outcomes (P for interaction in both outcomes = .045), with a possible beneficial effect in premenopausal women (contralateral breast cancer: adjusted hazard ratio [HR] = 0.66, and 95% confidence interval [ CI] = 0.41-1.07; ipsilateral breast cancer: adjusted HR = 0.65, and 95% CI = 0.46-0.92) and an opposite effect in postmenopausal women (contralateral breast cancer: adjusted HR = 1.32, and 95% CI = 0.82-2.15; ipsilateral breast cancer: adjusted HR = 1.19, and 95% CI = 0.75-1.89). There were no statistically significant differences between the two arms in tumors in other organs, incidence of distant metastasis, and all-cause mortality. CONCLUSIONS: Fenretinide treatment of women with breast cancer for 5 years appears to have no statistically significant effect on the incidence of second breast malignancies overall, although a possible benefit was detected in premenopausal women. These studies, particularly the post hoc analyses, are considered exploratory and need to be confirmed.
10 June 1998 in International Journal of Cancer
Growing evidence substantiates the role of the insulin‐like growth factor I (IGF‐I) system in breast tumorigenesis. Retinoids have been shown to affect the IGF system in several experimental models. We extended our previous data on plasma IGF‐I modulation by the synthetic retinoid fenretinide (4‐HPR) and investigated the effect of the retinoid on plasma IGF binding protein (BP)‐3, the major protein binding IGFs. IGF‐I and IGFBP‐3 were measured on plasma samples obtained at randomization and after an interval of approximately 1 year, from 39 and 33 stage I breast cancer patients assigned to receive 4‐HPR, and from 39 and 34 untreated controls, respectively. There was a significant decrease in plasma IGF‐I after 4‐HPR administration, whereas no significant change was observed in controls. The effect of 4‐HPR on IGF‐I levels was modified by menopausal status, inasmuch as the decrease in IGF‐I was particularly pronounced in pre‐menopausal women, whereas the reverse was observed in untreated controls. By contrast, treatment induced an increase of IGFBP‐3 with respect to controls. As a result of this dual effect, the bioavailability of IGF‐I for interaction with receptors at target levels further decreased in pre‐menopausal 4‐HPR‐treated patients compared with controls, suggesting that retinoid administration may result in lower concentrations of biologically active IGF‐I. Our findings may have important implications for the clinical preventive activity of this retinoid. Int. J. Cancer 76:787–790, 1998.